Pricing controls and reimbursement risk as a financial variable
# Pricing controls and reimbursement risk as a financial variable
In September 2024, the US government announced negotiated prices for the first ten drugs selected under Medicare's new drug price negotiation program, including Eliquis (a blood thinner from Bristol Myers Squibb and Pfizer) and Januvia (a diabetes drug from Merck). Some price cuts versus list price exceeded 50%. Those negotiated prices took effect in January 2026. For a company modeling a decade of future cash flows off a single drug, that is not a footnote. It is a step change in the revenue line.
This lesson treats pricing controls as a financial variable, not a policy debate. The core skill: knowing where list price ends and realized net price begins, and who takes the difference.
List price vs. net price: the core concept
List price (also called WAC, wholesale acquisition costacquisition costCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.View full definition →) is the sticker price a manufacturer sets. It is rarely what anyone actually pays.
Net price
is what the manufacturer actually keeps after rebates, discounts, chargebacks, and mandatory price cuts. In the US, the gap between list and net has widened for years; industry-funded estimates from groups like
put average manufacturer rebates and discounts across the US market at roughly 50% of list price for many branded drugs as of recent years (estimate, varies widely by product and payer).
This gap is the single most important number in pharma revenue analysis. A drug with $10 billion in list-price sales might generate $5 to 6 billion in actual net revenue once rebates are stripped out.
The three big compression mechanisms
1. medicare negotiation under the IRA
The Inflation Reduction Act (IRA), passed in 2022, gave the US government direct price-setting power over Medicare (the federal health insurance program for people 65+) for the first time. The Centers for Medicare & Medicaid Services (CMS) selects high-spend drugs with no generic or biosimilar competition and negotiates a "maximum fair price."
Mechanics that matter financially:
Small-molecule drugs (typical pills) become eligible for negotiation 9 years after FDA approval.
Biologics (complex, large-molecule drugs like antibodies) get 13 years, a meaningful difference in effective patent-protected pricing life.
A second batch of negotiated prices for more drugs takes effect in 2027, with CMS naming selected drugs on a rolling annual cycle.
Manufacturers that refuse to negotiate face an excise tax that can reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → up to 95% of US sales of the drug, making non-participation effectively unworkable.
Financial read: model a "negotiation cliff" into terminal value assumptions for any drug approaching its 9 or 13 year mark with Medicare as a material payer channel.
2. external reference pricing in europe
Most European countries do not negotiate blind. They use external reference pricing (ERP): setting a national price by benchmarking against prices in a defined basket of other countries.
Germany's AMNOG process (Arzneimittelmarktneuordnungsgesetz, the 2011 law governing new drug pricing) requires manufacturers to prove "additional benefit" over existing therapy to the G-BA (Federal Joint Committee) before a negotiated price applies; drugs judged to have no added benefit get referenced to existing treatment cost.
The financial risk compounds across borders: because many countries reference each other's list prices, a discount granted in one market (say, to unlock volume in a smaller economy) can drag down list prices the manufacturer can sustain elsewhere. This is why manufacturers sometimes prefer confidential rebates over public list-price cuts in Europe, to avoid triggering reference-price contagion.
3. payer rebates in the US commercial market
Even outside Medicare, US list prices are compressed by pharmacy benefit managers (PBMs), the intermediaries (CVS Caremark, Express Scripts, OptumRx dominate the market) that negotiate rebates from manufacturers in exchange for favorable formulary placement (which drugs an insurance plan covers, and at what tier).
A manufacturer might set WAC at $1,000 per unit, pay a 40% rebate to the PBM to secure formulary access, and net roughly $600. The list price never changes publicly, but realized revenue does.
A worked example
Take a hypothetical branded drug with $4 billion in annual gross (list-price) US sales.
Assume average gross-to-net rebate rate: 45% (estimate, consistent with industry-wide averages reported by IQVIA and PhRMA in recent years)
Net US revenue = $4B × (1 − 0.45) = $2.2 billion
Now assume this drug is selected for Medicare negotiation in year 9, and the negotiated price represents a further 30% cut on the Medicare-channel portion, which is 40% of total US volume.
New total gross sales: $1.12B + $2.4B (non-Medicare) = $3.52B
Apply the same 45% average rebate rate to remaining volume: net revenue ≈ $1.94 billion
That is roughly a 12% net revenue decline from one policy mechanism alone, layered on top of ordinary competitive erosion. This is the kind of sensitivity table due-diligence teams should build for any drug over $1 billion in US sales approaching its negotiation eligibility window.
Knowledge check
1. In pharma financial analysis, why is the gap between list price and net price considered the single most important number for revenue modeling?
2. A company is building a 10-year discounted cash flow model for a top-selling Medicare-covered drug. Why does the IRA's Medicare negotiation program matter specifically for this kind of long-horizon modeling?
3. Which statement best captures the distinction between 'list price' and 'net price' as financial variables?
MULTIPLE CHOICE
4. Select ALL correct answers about why analysts should treat pricing controls as a 'financial variable' rather than purely a policy debate.
Select all the correct answers.
MULTIPLE CHOICE
5. Select ALL correct answers about the mechanics of the gap between list price and net price for branded drugs in the US.
Select all the correct answers.
Financial due-diligence checks
When evaluating a pharma company, portfolio drug, or licensing deal, treat pricing exposure as a risk factor to underwrite explicitly:
Check the payer mix. What share of revenue runs through Medicare, Medicaid, commercial insurance, and ex-US public payers? Higher Medicare exposure means earlier negotiation risk.
Check patent and exclusivity timelines against IRA eligibility windows. A biologic in year 11 has two years of negotiation risk left before eligibility; a small molecule in year 8 has one.
Check gross-to-net trend, not just the current rebate rate. A rising rebate rate over several quarters signals eroding pricing power even before headline list price changes.
Check reference-pricing basket exposure in Europe. Is the company launching first in a low-price reference country, potentially anchoring prices downward across the EU?
Check disclosure quality. Under SEC rules, US-listed pharma companies must discuss material pricing and reimbursement risk in the "Risk Factors" section of the 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition → annual report; treat vague boilerplate language here as a red flag, not reassurance. The CMS Drug Price Negotiation Program page lists selected drugs and negotiated prices directly.
Key Takeaways
List price is a starting point, not a forecast; net price after rebates and mandatory discounts is what belongs in any real revenue model, and the gap commonly runs near 40 to 50% in the US (estimate).
The IRA created a hard, dated financial event for eligible drugs: Medicare negotiation kicks in at year 9 (small molecules) or year 13 (biologics), with published price cuts that have exceeded 50% in the first cohort.
European reference pricing means a discount in one country can propagate across a whole reference basket, so pricing strategy is a cross-border financial decision, not a local one.
Build gross-to-net bridges and negotiation-eligibility timelines into any due-diligence model; a single mechanism can plausibly compress net revenue by low double digits on a major product.
Treat payer mix concentration (Medicare share, PBM rebate dependency) as a quantifiable risk factor, checkable against 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition → disclosures and CMS public data.